TINN2: Treat Infection in NeoNates 2

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2018

Conditions
Bronchopulmonary Dysplasia
Interventions
DRUG

Azithromycin

Azithromycin IV 10mg/kg daily for 10 days

DRUG

Placebo

Azithromycin placebo (5% Dextrose) daily for 10 days

Trial Locations (16)

Unknown

Centre Hospitalier Chrétien (CHC), Liège

Assistance Publique Hôpitaux de Paris (APHP), Paris

Inserm-Transfert (IT), Paris

Institut National de la Santé et de la Recherche Médicale (INSERM), Paris

Only for children pharmaceuticals (04CP), Paris

Heinrich-Heine-Universität Düsseldorf (UDUS), Düsseldorf

University of Ulm (UUlm), Ulm

Semmelweis University Budapest, Faculty of Medicine (SOTE), Budapest

Pandy Kalman County Hospital, Gyula

Mario Negri Institute (IRFMN), Milan

Advanced Biological Laboratories ABL (ABL SA), Luxembourg

Erasmus-University Medical Center (ERAMUS), Rotterdam

Karolinska Institutet (KI), Stockholm

Cardiff University (CU), Cardiff

University of Liverpool (UOL), Liverpool

Simcyp Limited (SimCyp), Sheffield

All Listed Sponsors
collaborator

University of Liverpool

OTHER

collaborator

Cardiff University

OTHER

collaborator

University of Nottingham

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Heinrich-Heine-Universität Düsseldorf (UDUS)

UNKNOWN

collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

collaborator

Mario Negri Institute (IRFMN)

UNKNOWN

collaborator

Advanced Biological Laboratories ABL (ABL SA)

UNKNOWN

collaborator

Simcyp Limited (SimCyp)

UNKNOWN

collaborator

Only For Children Pharmaceuticals

INDUSTRY

collaborator

University of Ulm

OTHER

collaborator

Karolinska Institutet

OTHER

collaborator

Centre Hospitalier Chrétien (CHC)

UNKNOWN

collaborator

Semmelweis University

OTHER

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV